Patent classifications
C12N11/00
Apparatus for preparing immobilized-enzyme beads and method for preparing immobilized-enzyme beads using same
The present invention relates to an apparatus for preparing enzyme-immobilized beads used for preparation of tagatose, and a method for preparing enzyme-immobilized beads using the same. More specifically, the present invention relates to an apparatus for preparing enzyme-immobilized beads, comprising a nozzle with an inside diameter of 0.1-1 mm having a cylindrical lower end and comprising a cut-type liquid outlet (cut perpendicularly to the vertical axis of the nozzle) formed at the lower end, and a method for preparing enzyme-immobilized beads using the same.
Bioreversible boronates for delivery of molecules into cells
Methods for enhancing cellular uptake of cargo molecules by boronating the cargo molecule, particularly with one or more phenylboronic acid groups. Boronation reagents for reversible boronation of cargo molecules, particularly, cargo molecules having one or more amino groups are provided.
Bioreversible boronates for delivery of molecules into cells
Methods for enhancing cellular uptake of cargo molecules by boronating the cargo molecule, particularly with one or more phenylboronic acid groups. Boronation reagents for reversible boronation of cargo molecules, particularly, cargo molecules having one or more amino groups are provided.
3-epimerase
A protein comprising a polypeptide sequence having at least 70% sequence identity to SEQ ID NO:6, SEQ ID NO:2 or SEQ ID NO:4. The protein has ketose 3-epimerase activity.
Modified Phenylalanine Dehydrogenase
The present invention provides a unit and a method useful for more precise phenylalanine measurement. More specifically, the present invention provides a modified phenylalanine dehydrogenase that includes a mutation of at least one amino acid residue so as to improve the characteristics (for example, substrate specificity, solubility, and phenylalanine dehydrogenase activity) of a phenylalanine dehydrogenase related to measurement of phenylalanine, a method for analyzing phenylalanine by measuring phenylalanine contained in a test sample using the modified phenylalanine dehydrogenase, and others.
Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution
Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. Solid-phase microbead-immobilization is used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. MTG remained firmly immobilized with no detectable column bleeding and enzyme activity was sustained during continuous operation. Immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted when the conjugation was carried out in solution. The generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody. Site-specific glutamine conjugation with small peptides containing a lysine residue and a functional moiety is also described.
Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution
Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. Solid-phase microbead-immobilization is used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. MTG remained firmly immobilized with no detectable column bleeding and enzyme activity was sustained during continuous operation. Immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted when the conjugation was carried out in solution. The generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody. Site-specific glutamine conjugation with small peptides containing a lysine residue and a functional moiety is also described.
METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE
The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer.
METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE
The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer.
ENTERIC COMPOSITION, FOOD OR BEVERAGE PRODUCT CONTAINING THE SAME, METHOD FOR CONTROLLING DISINTEGRATION TIME OF THE SAME, AND METHOD FOR MANUFACTURING THE SAME
PROBLEM TO BE SOLVED: There is provided an enteric composition that is suitable for addition to food or beverage products, such as yogurt, and has a disintegration time that is controllable to enable disintegration and content release in the small intestine or the large intestine, especially in the large intestine.
SOLUTION: An enteric composition includes a content and an enteric coating agent, the content being a mixture of probiotics and an edible hydrogenated oil emulsion, the content being coated with the enteric coating agent.